The Future of Medical Guidelines: Standardizing Clinical Care With the Humility of Uncertainty.

Ann Intern Med

Department of Medicine, University of Alabama Medical Center, and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama (T.S., R.M.C.).

Published: December 2021

Download full-text PDF

Source
http://dx.doi.org/10.7326/M21-3034DOI Listing

Publication Analysis

Top Keywords

future medical
4
medical guidelines
4
guidelines standardizing
4
standardizing clinical
4
clinical care
4
care humility
4
humility uncertainty
4
future
1
guidelines
1
standardizing
1

Similar Publications

Insights into NEK2 inhibitors as antitumor agents: From mechanisms to potential therapeutics.

Eur J Med Chem

January 2025

Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Healthand, Department of Frontiers Science Center for Disease-related Molecular Network, Core Facilities, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. Electronic address:

NEK2, a serine/threonine protein kinase, is integral to mitotic events such as centrosome duplication and separation, microtubule stabilization, spindle assembly checkpoint, and kinetochore attachment. However, NEK2 overexpression leads to centrosome amplification and chromosomal instability, which are significantly associated with various malignancies, including liver, breast, and non-small cell lung cancer. This overexpression could facilitate tumor development and confer resistance to therapy by promoting aberrant cell division and centrosome amplification.

View Article and Find Full Text PDF

Background: Delayed cerebral ischemia (DCI) is a primary contributor to death after subarachnoid hemorrhage (SAH), with significant incidence. Therefore, early determination of the risk of DCI is an urgent need. Machine learning (ML) has received much attention in clinical practice.

View Article and Find Full Text PDF

Current literature is unclear on the safety and optimal timing of delivery for pregnant individuals with gestational diabetes mellitus, which inspired our study team to conduct a web-based survey study exploring patient and provider opinions on delivery options. However, an incident of fraudulent activity with survey responses prompted a shift in the focus of the research project. Unfortunately, despite the significant rise of web-based surveys used in medical research, there remains very limited evidence on the implications of and optimal methods to handle fraudulent web-based survey responses.

View Article and Find Full Text PDF

To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD). This was a phase 2, multinational, randomized, double-blind, placebo controlled trial. Patients were randomized to oral placebo or BI 1358894 (5 mg, 25 mg, 75 mg, or 125 mg) once daily in a 2.

View Article and Find Full Text PDF

Characterization of Tumor Antigens from Multi-omics Data: Computational Approaches and Resources.

Genomics Proteomics Bioinformatics

January 2025

Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77030, USA.

Tumor-specific antigens, also known as neoantigens, have potential utility in anti-cancer immunotherapy, including immune checkpoint blockade (ICB), neoantigen-specific T cell receptor-engineered T (TCR-T), chimeric antigen receptor T (CAR-T), and therapeutic cancer vaccines (TCVs). After recognizing presented neoantigens, the immune system becomes activated and triggers the death of tumor cells. Neoantigens may be derived from multiple origins, including somatic mutations (single nucleotide variants, insertion/deletions, and gene fusions), circular RNAs, alternative splicing, RNA editing, and polymorphic microbiome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!